Study Title: A Multicenter, Prospective, Modified Platform Trial Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers.

NCT07665268 | Recruiting Phase 4

• 1 other identifier: Pro00092936
• Study Type: interventional
• Target: 2,000
• Locations: 1 country
• Sites: 1

Brief Summary

A multicenter prospective modified platform trial evaluating several cellular, acellular, and matrix like products and standard of care versus matched standard of care controls in the management of nonhealing pressure ulcers.

Conditions

Skin Ulcer; Pressure Ulcer (PU); Pressure Ulcer of Skin; Pressure Sore; Chronic Ulcer; Pressure Wound

Keywords

Ulcer; Pressure; Pressure Ulcer; Pressure Sore; Skin Ulcer; Pressure Ulcer of Skin; Chronic Ulcer; Wound

Outcome Measures

Primary Outcomes (1)

• Between Arm Difference for Complete Closure

  Determine the between-arm difference in the proportion of subjects achieving complete closure of nonhealing pressure ulcers with multiple CAMPs plus SOC versus matched SOC controls (mSOC) over 20 weeks using a modified platform trial design.

  0-20 Weeks

Secondary Outcomes (4)

• Time to Closure

  0-20 Weeks

• Percentage Area Reduction

  0-20 Weeks

• Pain Scale Reduction

  0-20 Weeks

• Adverse Events

  0-20 Weeks

Other Outcomes (4)

• Evaluate Quality of Life

  0-20 Weeks

• Compliance with Off-loading

  0-20 Weeks

• Ulcers to Close in Patients over 65

  0-20 Weeks

Study Arms (5)

Activate™ Matrix + SOC

EXPERIMENTAL

Three layers: amnion, intermediate layer, and chorion

Other: Activate™ Matrix + SOC

AmnioDefend™ FT Matrix + SOC

EXPERIMENTAL

Three layers: amnion, intermediate layer, and chorion

Other: AmnioDefend™ FT Matrix + SOC

Palisade™ DM Matrix + SOC

EXPERIMENTAL

Two layers: amnion and chorion

Other: Palisade™ DM Matrix + SOC

Sentry™ SL Matrix + SOC

EXPERIMENTAL

One layer: amnion

Other: Sentry™ SL Matrix + SOC

Shelter™ DM Matrix + SOC

EXPERIMENTAL

Two layers: amnion and chorion

Other: Shelter™ DM Matrix + SOC

Interventions

Activate™ Matrix + SOC OTHER

Participants will receive weekly applications of Activate™ Matrix and Standard of Care until ulcer closure, or a maximum of 20 weeks, whichever occurs first.

Activate™ Matrix + SOC

AmnioDefend™ FT Matrix + SOC OTHER

Participants will receive weekly applications of AmnioDefend™ FT Matrix and Standard of Care until ulcer closure, or a maximum of 20 weeks, whichever occurs first.

AmnioDefend™ FT Matrix + SOC

Palisade™ DM Matrix + SOC OTHER

Participants will receive weekly applications of Palisade™ DM Matrix and Standard of Care until ulcer closure, or a maximum of 20 weeks, whichever occurs first.

Palisade™ DM Matrix + SOC

Sentry™ SL Matrix + SOC OTHER

Participants will receive weekly applications of Sentry™ SL Matrix and Standard of Care until ulcer closure, or a maximum of 20 weeks, whichever occurs first.

Sentry™ SL Matrix + SOC

Shelter™ DM Matrix + SOC OTHER

Participants will receive weekly applications of Shelter™ DM Matrix and Standard of Care until ulcer closure, or a maximum of 20 weeks, whichever occurs first.

Shelter™ DM Matrix + SOC

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The potential subject must be at least 18 years of age or older.
• The potential subject must agree to attend the weekly study visits required by the protocol.
• The potential subject must be willing and able to participate in the informed consent process.
• The potential subject must have a full-thickness pressure ulcer NPIAP stage 3 or stage 4 without exposed tendon or bone of greater than or equal to one month in duration located on the trunk (sacral, trochanteric, or ischial).
• At enrollment, the potential subject must have a target ulcer with a minimum surface area of 2 cm2 and a maximum surface area of 100cm2 measured post-debridement with the imaging device.
• The potential subject has adequate off-loading of the ulcer

You may not qualify if:

• The potential subject is known to have a life expectancy of \< 3 months.
• The potential subject's target ulcer is not a pressure ulcer.
• The target ulcer is infected, requires systemic antibiotic therapy, or there is cellulitis in the surrounding skin.
• The target ulcer exposes tendon or bone.
• The target ulcer has undermining or tunneling.
• There is evidence of osteomyelitis complicating the target ulcer.
• The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics).
• The potential subject has applied topical steroids to the ulcer surface within one month of initial screening.
• The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.
• The surface area of the potential subject's target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit ("historical" run-in period). Imaging Device is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length × width is acceptable).
• The surface area measurement of the potential subject's target ulcer decreases by 25% or more during the active 2-week screening phase: the 2 weeks from the initial screening visit (S1) to the TV-1 visit during which time the potential subject received SOC. - The potential subject is a woman who is pregnant or considering becoming pregnant within the next 6 months.
• The potential subject has end stage renal disease requiring dialysis.
• The potential subject, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments.
• The potential subject was treated with hyperbaric oxygen therapy (HBOT) or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to the initial screening visit.
• The potential subject has a malnutrition indicator score of \<17 as measured on the Mini Nutritional Assessment.

Sponsors & Collaborators

• Sequence LifeScience, Inc.: lead
• Serena Group: collaborator

Study Sites (1)

Amber Stormer

North Royalton, Ohio, 44133, United States

RECRUITING

MeSH Terms

Conditions

Skin Ulcer; Pressure Ulcer; Ulcer; Wounds and Injuries

Condition Hierarchy (Ancestors)

Skin Diseases; Skin and Connective Tissue Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Thomas Serena, MD

  Serena Group

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Bennett Sarver

CONTACT

1-833-865-6300; info@serenagroups.com

Amy Allen

CONTACT

1-833-865-6300; info@serenagroups.com

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Prospective Modified Platform Multicenter Clinical Trial Utilizing Matched Controls.

Study Record Dates

• First Submitted: May 21, 2026
• First Posted: June 24, 2026
• Study Start: January 28, 2026
• Primary Completion (Estimated): January 28, 2028
• Study Completion (Estimated): January 28, 2028
• Last Updated: June 24, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)